
Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases. The company has developed a unique platform that integrates medicinal chemistry and systems biology through machine learning to identify and develop novel drugs targeting autoimmune and chronic inflammatory diseases. Their mission is to harness the power of science and artificial intelligence to improve human health, focusing on specific subtypes of patients with these conditions.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases. The company has developed a unique platform that integrates medicinal chemistry and systems biology through machine learning to identify and develop novel drugs targeting autoimmune and chronic inflammatory diseases. Their mission is to harness the power of science and artificial intelligence to improve human health, focusing on specific subtypes of patients with these conditions.
Stage: Clinical-stage biotechnology company
Focus: AI-driven precision small-molecule therapeutics for autoimmune and inflammatory diseases
Lead program: ATH-063, an oral G9A inhibitor (Phase 1 topline positive results reported Oct 16, 2024)
Founded: 2019
Total funding (reported): USD 54,250,000 (aggregate reported)
Autoimmune and chronic inflammatory diseases, including inflammatory bowel disease (ulcerative colitis).
2019
Biotechnology
Series B announced Feb 16, 2024; media reported raises around $35M to support clinical trials.